 |
 |
NCCN指南已经将CPT-11联合铂类列为晚期非小细胞肺癌一线治疗方案。本项研究结果显示，CPT-11+DDP治疗晚期NSCLC疗效确切，用药剂量患者尚可耐受，对于CPT-11所导致的骨髓抑制及腹泻反应及早进行干预，但对于晚期复治及多程治疗后患者及KPS评分<70分患者，如何使用CPT-11值得进一步深入研究。
【参考文献】
[1] 程刚.晚期非小细胞肺癌的研究进展[M]∥马军，秦叔逵.中国临床肿瘤学教育专辑.北京:中国协和医科大学出版社，2009：14-18.
[2] Crinò L, Scagliotti G, Marangolo M, et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study [J]. J Clin Oncol，1997，15(1):297-303.
[3] Comer AM, Goa KL. Docetaxel: a review of its use in non-small cell lung cancer [J]. Drugs Aging，2000，17(1):53-80.
[4] Gebbia V, Caruso M, Valenza R, et al. Vinorelbine plus cisplatinum for the treatment of stage IIIB and IV non small cell lung carcinoma [J]. Anticancer Res，1994，14(3B):1247-1249.
[5] 杨学宁，吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90;111.
[6] Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [J]. N Engl J Med，2002，346(2):92-98医.学全.在.线网站www.lindalemus.com.
[7] Masuda N, Fukuoka M, Kudoh S, et al. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer [J]. J Clin Oncol，1994，12(1):90-96.
[8] DeVore RF, Johnson DH, Crawford J, et al. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer [J]. J Clin Oncol， 1999，17(9):2710-2720.
[9] Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan [J]. Ann Oncol，2007，18(2):317-323.
